Search

Your search keyword '"Rathi, Komal S."' showing total 85 results

Search Constraints

Start Over You searched for: Author "Rathi, Komal S." Remove constraint Author: "Rathi, Komal S." Database Unpaywall Remove constraint Database: Unpaywall
85 results on '"Rathi, Komal S."'

Search Results

1. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

2. OpenPBTA: The Open Pediatric Brain Tumor Atlas

3. Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality

4. Figures S1-7 from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

5. Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

6. Supplementary Figure from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

7. Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

8. Data from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

9. Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

10. Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

11. Supplementary Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

12. Data from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

13. Figures S1-7 from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

14. Supplementary Figure from MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

15. Data from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

16. Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models

17. Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models

18. Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models

33. Supplementary Data from OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

35. Supplementary Data from OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

37. Supplementary Data from GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma

38. Supplementary Data from GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma

39. Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

41. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma

42. Targeted gene expression profiling of inverted papilloma and squamous cell carcinoma

43. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

44. NASA GeneLab RNA-seq consensus pipeline: Standardized processing of short-read RNA-seq data

45. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target

46. Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality

47. GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma

48. MYCcontrols metastatic heterogeneity in pancreatic cancer

49. annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions

50. Abstract PO-053: MYC Influences metastatic heterogeneity in pancreatic cancer

Catalog

Books, media, physical & digital resources